UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 17, 2010
Javelin Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
| | | | | |
| Delaware | | 001-32949 | | 88-0471759 |
| | | | | |
(State or other jurisdiction of
incorporation) | | (Commission
File Number) | | (I.R.S. Employer
Identification No.) |
| | | |
| 125 CambridgePark Drive, Cambridge Massachusetts | | 02140 |
| | | |
| (Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code (617) 349-4500
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (seeGeneral Instruction A.2. below):
| | |
| þ | | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| | |
| o | | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| | |
| o | | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| | |
| o | | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
On February 17, 2010, Javelin Pharmaceuticals, Inc. issued a press release announcing that its New Drug Application submitted on December 2, 2009 to the US Food and Drug Administration (FDA) for its investigational product candidate, Dyloject™ (diclofenac sodium) Injection, has received an FDA Prescription Drug User Fee Act date of October 3, 2010. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
| | |
| Item 9.01 | | Financial Statements and Exhibits |
(d) Exhibits.
| | | | | |
| Exhibit No. | | Description |
| | 99.1 | | | Press Release of Javelin Pharmaceuticals, Inc. dated February 17, 2010 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | |
| | JAVELIN PHARMACEUTICALS, INC.
| |
| | By: | /s/ Martin J. Driscoll | |
| | | Name: | Martin J. Driscoll | |
| | | Title: | Chief Executive Officer | |
| |
Dated: February 17, 2010
EXHIBIT INDEX
| | | | | |
| Number | | Document |
| | 99.1 | | | Press Release of Javelin Pharmaceuticals, Inc. dated February 17, 2010 |
